HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Clinical trials for HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST explained in plain language.
Never miss a new study
Get alerted when new HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST trials appear
Sign up with your email to follow new studies for HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill takes aim at Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…
Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
New combo aims to outsmart resistant breast cancer
Disease control Recruiting nowThis study tests whether adding elacestrant to standard chemotherapy (capecitabine) can help people with advanced estrogen receptor-positive (ER+) breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to get either the combi…
Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New pill aims to shrink tumors in advanced breast and ovarian cancers
Disease control Recruiting nowThis study tests a new daily pill, INX-315, in 150 people with advanced breast, ovarian, or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The study includes three parts: testing the…
Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Phase: PHASE1, PHASE2 • Sponsor: Incyclix Bio • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New hope for nigerian women: targeted breast cancer therapy before and after surgery
Disease control Recruiting nowThis study is for Nigerian women with a specific type of breast cancer called HER2-positive. Doctors want to see if giving a combination of targeted drugs before and after surgery can destroy the cancer completely. About 74 women will receive the treatment, and researchers will c…
Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 11, 2026 20:48 UTC